BRAF and cancer: Sorafenib, a small molecule multi-kinase inhibitor, targets Raf-1, B-Raf, vascular endothelial growth factor receptors (VEGFRs) [2,22,], and PDGFR-β (platelet-derived growth factor receptor β) involved in cancer cell proliferation, angiogenesis, and invasion in a wide range of cancer cells [23,24,].